pepdex
← Back to index
№ 035

SS-31 (Elamipretide / MTP-131)

Mitochondria-targeting peptide. Concentrates in inner mitochondrial membrane and supports ATP production. Real Phase 2/3 data in mitochondrial disease.

Metabolic
Evidence: Moderate
Half-life
~2-4 hours
Route
Subcutaneous
Cycle
4-8 weeks
Schedule
Once daily
In plain English

SS-31 (also called Elamipretide or MTP-131) targets your mitochondria — the energy plants inside your cells. It concentrates in the inner mitochondrial membrane and supports ATP production. Used by people with mitochondrial-flavored fatigue and as a longevity adjunct.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational (Stealth BioTherapeutics — Elamipretide). Multiple Phase 2/3 trials in mitochondrial disease.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Available through expanded-access in some mitochondrial-disease contexts. Not commercially available.

Who it's for

  • →Users with mitochondrial-flavored fatigue
  • →Older adults targeting cellular bioenergetics
  • →Stack add-ons for hard-training athletes

What to expect

  1. Week 1

    Subtle. Some users notice fatigue lifting first.

  2. Week 4

    Cumulative endurance / recovery improvements for responders.

  3. Week 8

    Plateau. Cycle off.

How it works (mechanism)

Mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin. Stabilizes the electron transport chain and improves ATP production efficiency under stress.

Dosing protocol

5-40 mg sub-q daily, depending on indication. Most casual users run 5-10 mg.

Stacks well with

MOTS-c for combined mitochondrial support
Standalone

Side effects

01Generally well tolerated
02Injection-site irritation
03Rare: headache

When NOT to use

  • ⚠Pregnancy / nursing
  • ⚠No data in active malignancy

Common mistakes

  • • Expecting fast effects (it's cumulative)
  • • Running short cycles and quitting before adaptation
  • • Underdosing for therapeutic context

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is SS-31 (Elamipretide / MTP-131)?+
SS-31 (also called Elamipretide or MTP-131) targets your mitochondria — the energy plants inside your cells. It concentrates in the inner mitochondrial membrane and supports ATP production. Used by people with mitochondrial-flavored fatigue and as a longevity adjunct.
Is SS-31 (Elamipretide / MTP-131) FDA approved?+
Investigational (Stealth BioTherapeutics — Elamipretide). Multiple Phase 2/3 trials in mitochondrial disease.
Is SS-31 (Elamipretide / MTP-131) banned by WADA?+
SS-31 (Elamipretide / MTP-131) is not currently on the WADA prohibited list.
Are you still natty after taking SS-31 (Elamipretide / MTP-131)?+
No. SS-31 (Elamipretide / MTP-131) is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe SS-31 (Elamipretide / MTP-131)?+
Available through expanded-access in some mitochondrial-disease contexts. Not commercially available.
What's the typical dose of SS-31 (Elamipretide / MTP-131)?+
5-40 mg sub-q daily, depending on indication. Most casual users run 5-10 mg.
What are the side effects of SS-31 (Elamipretide / MTP-131)?+
Common side effects include: Generally well tolerated; Injection-site irritation; Rare: headache. Less common effects and full safety details are on the entry page.
How long until SS-31 (Elamipretide / MTP-131) starts working?+
Subtle. Some users notice fatigue lifting first.

More in Metabolic

№ 020
MOTS-c

Mitochondrial-derived peptide. Targets metabolic flexibility, insulin sensitivity, and exercise response.